UBS Upgrades InterMune (ITMN) to Neutral
More News related to ITMN
- InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
- InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
- InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
More News related to Upgrades
- S&P Announces Change to US Index: LL for UCBH
- Electronic Arts (ERTS) Makes Major Job Cuts As Q2 Profits Lag
- Kraft (KFT) to Ask Holders to Vote to Issue New Shares
- Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
- Highlights From DISH's Q3 Conference Call - Q&A Session
UBS upgrades InterMune (Nasdaq: ITMN) from Sell to Neutral. Price target $13.
InterMune, Inc. (InterMune) is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology.
To see more analyst ratings on ITMN Click Here.
Related Categories
UpgradesStocks Mentioned
+0.71Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
